The benefits of 5,000L singleuse bioreactors for biologics manufacturing

The market for complex biologics including monoclonal antibodies, bispecific antibodies and fusion molecules is growing at a rapid pace. Recent estimates suggest the global market for monoclonal antibodies will grow 11% annually to reach nearly $500 billion in 2030.1 The global market for fusion proteins is expected to grow 4% a year to $33 billion in 2030,2 and the market for bispecific antibodies is projected to expand at a rapid 43% per year to $110 billion in that time period.

This unprecedented growth is increasing the pressure on biopharma developers and their partners to improve efficiencies at every stage of the manufacturing process. Ensuring that the correct manufacturing capacity is in place for a new biologic is an essential part of that process.